New CMS reimbursement rates are pressuring Medicare Advantage profits, sending shares of Humana and CVS Health lower. We analyze whether the sell-off presents a buying opportunity for dividend investors or signals deeper structural challenges.
RBC Capital reaffirms its Outperform rating on UnitedHealth Group, citing management's commitment to long-term earnings targets, even as a lower-than-expected Medicare Advantage rate proposal triggers a sharp sell-off in the health insurer's shares.
As the Federal Reserve signals potential rate cuts, income-focused investors are re-evaluating their portfolios. We analyze seven dividend ETFs that offer resilient income streams and capital appreciation potential when bond yields decline.
With low adoption rates for brokerage 'trusted contacts,' regulators are considering a simple name change to 'emergency contact' to reduce confusion, ease client concerns, and strengthen protections against financial exploitation.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Morgan Stanley reaffirms its Overweight rating on NIO Inc., maintaining a $7 price target. Analyst Tim Hsiao highlights the EV maker's plan for 40-50% annual delivery growth through 2026 and improved strategic focus following a meeting with founder William Li.
The global lifestyle retailer MINISO continues its aggressive capital return strategy, repurchasing millions of shares under a Rule 10b5-1 program as analysts remain bullish on the stock's outlook.
Soybean prices extended their decline on Friday, pressured by lackluster export sales data and a broader commodity sell-off. With key commitments lagging last year's pace, traders are now looking ahead to next week's crush data for signs of domestic demand strength.
While Wall Street analysts are overwhelmingly bullish on several stocks, their optimistic price targets often come with a caveat. We examine one company where the enthusiasm appears justified and two where underlying challenges suggest a more cautious approach.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, they can also mask underlying vulnerabilities. We analyze three such stocks—Figs, Array Technologies, and Kforce—that currently present significant risks to investors, despite their seemingly accessible price tags.
While small-cap stocks can offer overlooked opportunities, their high-risk nature demands careful scrutiny. We examine three companies where valuation and business concerns suggest caution may be warranted.
While stocks priced between $10 and $50 can offer an appealing mix of accessibility and relative maturity, savvy investors know the sticker price is just the beginning. We examine one company in this range that appears poised for growth and two where the fundamentals warrant a closer, more cautious look.
A strategic report warns that recent tariff hikes could significantly increase clothing costs for American shoppers unless brands rapidly diversify production to a network of partner nations.
While robust cash generation is a hallmark of a healthy business, it doesn't automatically translate to a sound investment. We examine three companies with strong free cash flow margins where valuation and strategic concerns give investors pause.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.
Valley National Bancorp (VLY) reported fourth-quarter revenue and profit that topped Wall Street forecasts, driven by robust core deposit growth and disciplined balance sheet management. The regional bank's leadership pointed to strategic tech investments and commercial loan demand as key pillars for its 2025 outlook.
Secretary-General António Guterres warns the United Nations could exhaust its regular budget cash by July, citing chronic non-payment of dues by member states and a "Kafkaesque" financial cycle that threatens its core operations.
TAL Education Group's stock soared following robust Q3 FY2026 results and a new share repurchase program, marking a potential inflection point for the Chinese tutoring giant navigating a post-regulatory landscape. Analysts debate if the rally signals a lasting recovery or a temporary reprieve.
